The writer of cardiac regular management products is anticipating rising demand overseas, and at place of abode has a robust balance sheet and cash flow

Watch original video:

St. Jude Medical—52-week stock price

By Gene Marcial

For certain types of health care, spending isn’t discretionary: When you are having, say, a heart puzzle, you don’confidentially postpone treatment or medical help. So you would think that makers of life-saving sanatory devices would be classic defensive (i.e., recession-resistant) plays. Yet the stock market has been, well, destitute of spirit, as health-care stocks be the subject of been battered with the balance of the market.

But that’s entirely the additional reason why some stocks in the sector gain become compelling buys. After all, many of the companies that have been smacked on all sides have compact fundamentals, and the estimation declines have made them more attractive.

One example: St. Jude Medical (STJ), a leading maker of cardiac rhythm management devices, including implantable cardioverter defibrillators (ICDs). These devices are used to treat hearts that beat overmuch fast by monitoring the heartbeat and delivering high-energy electric impulses to stop the erratic beating. St. Jude moreover makes pacemakers and other cordial devices.

Shares of St. Jude, preference most other shares, have been walloped: It’s down to 30 a have a portion of on Dec. 9, from a 52-week high of 48.49 on July 17. In 2006, the stock traded as high 54.80. Its current price-earnings rate of 13.6 compares with its five-year high of 51 in 2005.

Health Profit Outlook

But the decline hasn’t turned off the bulls. "We continue to view St. Jude similar to attractively positioned to deliver sustained and above-average market sales and income growth," says analyst Michael Jungling of Merrill Lynch (MER), who rates the stock a buy, in a Dec. 2 report.

Because of the effects of the stronger U.S. dollar on overseas sales, St. Jude has lowered its forecasts for the fourth quarter, prompting analysts to divide their own estimates as well. Nonetheless, Wall Street remains generally bullish on the stock, with 18 analysts recommending it as a buy and 9 rating it a hold, according to data from Bloomberg. Only one algebraist tags it a sell.

Original text: {news-link}